Cannabotech, a biomedical startup based in Israel that focuses on the development of botanical treatments for preventive and integrative medicine, has announced that it has been granted exclusive use of a patent for the development of pharmaceuticals based on a Cyathus Striatus fungus extract.
The fungus is being studied in the laboratory of Professor Fouad Fares, a molecular biologist and cancer researcher at the University of Haifa’s Faculty of Natural Sciences.
According to the agreement signed between Cannabotech and Carmel, the University of Haifa’s economic company, Cannabotech will develop a botanical drug for pancreatic and colon cancers based on a combination of cannabinoids from the cannabis plant and a fungus extract researched in Professor Fares’ laboratory and found to be effective in killing pancreatic and colon cancer cells and reducing the size of cancerous tumors in a mouse model.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
Dr. Alex Weissman, an organic chemist and former head of research and development at Chimagis Active Ingredients Factory (API), and Dr. Isaac Angel, a pharmacologist with over 15 years of experience leading medication development processes, will aid Cannabotech in the research process.
Cannabotech recently announced the results of a study in which its CannaboBreast product for the treatment of breast cancer, which is based on a unique combination of cannabinoids and terpenes from the cannabis plant, when combined with standard chemotherapy, resulted in a 6-fold increase in cancer cell killing compared to existing treatment (from 10 percent to 60 percent cancer cell mortality).
“Cannabotech continues to advance in accordance with its business plan,” Cannabotech CEO Elhanan Shaked stated. Along with our preventative medicine products that are now accessible, we are conducting a range of clinical trials over the medium term, the most significant of which is the development of a botanical cancer medication based on a novel combination of cannabinoids and the Cyathus striatus fungus.”
“We are happy with the findings obtained thus far in animals and the important reduction in the number of cancerous tumors associated with increased cancer cell mortality,” Professor Fouad Fares stated. We are able to accelerate the research and development process through our collaboration with Cannabotech.”
Cannabotech has been creating a series of eight preparations based on a unique synergy of active molecules derived from the cannabis plant and fungus that act on two critical systems in the human body: the endocannabinoid system and the immune system.